



PRESS RELEASE

Squarex, LLC, Announces the Hiring of Joseph Cunningham as CFO

Saint Paul, Minnesota, USA, 20 April 2021 - Squarex Pharma ("SQX"), a St. Paul, Minnesota, based company, announced they have hired Joseph Cunningham as the Company's Chief Financial Officer ("CFO"). Mr. Cunningham brings a deep experience in healthcare and pharmaceuticals including time with Healthcare Management Asia (Singapore), Systems for Health Management (a clinical trial data management company), AXM Pharma (China) and Gamma Pharmaceuticals. Previously, as an investment banker he worked for BNP Paribas and ANZ Investment Bank in Singapore, and London. He was also an economist for Polyconomics in New York. As an investment banker, he has raised over \$5 billion in new money transactions. Joe Graduated from Northeastern University (Boston) with a BS in Economics and has an MBA from the Thunderbird School of Global Management (Phoenix).

Hugh McTavish, Squarex's CEO, commented, "Joe is a great hire for Squarex especially at this stage of our company. He brings a multi-faceted background and an institutional toolbox to help realize Squarex's ambitions." Mr. McTavish continued, "Squarex is fund-raising for a Phase 2 FDA bridging study; and after will then complete a Phase 3 clinical trial. Joe is a perfect fit as we go through the fund-raising process."

Mr Cunningham commented, "I'm excited to join the Squarex team, the Company has a large market opportunity and I look forward to putting my fund-raising and corporate development skills to good use as we forge our path ahead."

About Squarex Pharma

Squarex is a late clinical-stage biopharmaceutical company focused on the development and the Company's commercialization of therapeutic candidates to address large market opportunities. Initially Squarex is focus on the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. The Company's lead product candidate, SQX770, has successfully completed three clinical trials.

Squarex's drug SQX770 is unique. A single topical application to the arm, (not the lip or face), has been shown in clinical trials to prevent cold sore outbreaks (oral herpes) in people with frequent outbreaks for four months.

Website: <https://squarex-pharma.com/>

For more information about Squarex and partnering opportunities for its Herpes Labialis preventative treatment, please contact:

Hugh McTavish, CEO Squarex Pharma Tel 651 492 0283 hmctavish@squarex-pharma.com